



**BEATING
CANCER
IS IN
OUR BLOOD.**

**A NEW BREED
OF CANCER
NON-PROFIT**

Driving Research
Accelerating Cures



**LEUKEMIA &
LYMPHOMA
SOCIETY®**



OUR MISSION


Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

Provide patients and families with hope, guidance, education and **SUPPORT**

Drive **ADVOCACY** for policies that protect patient access to lifesaving treatment

Fund **RESEARCH** to advance lifesaving treatments

LLS serves all blood cancers



1. SEER data, 2019; 2. LLS, 2017; Sekeres et al 2010. J Natl Compr Canc Netw 9:57-63; 3. see Titmarsh et al. 2014. Am J Hematol. 89: 581-7



Blood cancer impact

Every

3

minutes someone
is diagnosed with blood
cancer

Blood cancers are the

3rd

leading cause of
cancer death in the
US



































More than

33%

of blood cancer
patients do not
survive five years
after diagnosis

2017 & 2018 FDA APPROVALS FOR BLOOD CANCERS

LLS helped advance 34 of the 39 blood cancer treatments approved by the FDA in 2017 and 2018

Acute Lymphoblastic Leukemia	Acute Myeloid Leukemia	Chronic Lymphocytic Leukemia	Chronic Myeloid Leukemia	Hodgkin Lymphoma	Non-Hodgkin Lymphoma	Myeloma	Other
<p> calaspargase pegol-mkni * (Asparlas™)</p> <p>blinatumomab (Blinicyto®) for minimal residual disease positive ALL</p> <p> tisagenlecleucel * (Kymriah®) †</p> <p>inotuzumab ozogamicin * (Besponsa®)</p> <p>blinatumomab (Blinicyto®)</p>	<p> gilteritinib * (Xospata®)</p> <p> glasdegib * (Daurismo®)</p> <p> ivosidenib * (Tibsovo®)</p> <p> arsenic trioxide (Trisenox®)</p> <p> venetoclax (Venclexta®)</p> <p> enasidenib * (Idhifa®)</p> <p> midostaurin * (Rydapt®)</p> <p> daunorubicin and cytarabine (Vyxeos®)</p> <p> gemtuzumab ozogamicin (Mylotarg®)</p>	<p> duvelisib * (Copiktra™) also approved for small cell lymphocytic lymphoma and follicular lymphoma</p> <p> venetoclax (Venclexta®) also approved for small cell lymphocytic lymphoma</p>	<p> nilotinib (Tasigna®) for Ph+ pediatric chronic myeloid leukemia</p> <p> bosutinib (Bosulif®)</p> <p> dasatinib (Sprycel®) for Ph+ pediatric chronic myeloid leukemia</p>	<p> brentuximab vedotin (Adcetris®)</p> <p> pembrolizumab (Keytruda®)</p>	<p> brentuximab vedotin (Adcetris®) for peripheral T-cell lymphoma</p> <p> tisagenlecleucel (Kymriah®) †</p> <p> ibrutinib (Imbruvica®)</p> <p> pembrolizumab (Keytruda®)</p> <p>mogamulizumab * (Poteligeo®)</p> <p> axicabtagene ciloleucel * (Yescarta®) †</p> <p> acalabrutinib * (Calquence®)</p> <p> brentuximab vedotin (Adcetris®) for two rare subtypes of cutaneous T-cell lymphoma</p> <p> obinutuzumab (Gazyva®)</p> <p> rituximab hyaluronidase (Rituxan Hycela®) also approved for chronic lymphocytic leukemia</p> <p>copanlisib * (Aliqopa™)</p>	<p> carfilzomib (Kyprolis®)</p> <p> daratumumab (Darzalex®)</p> <p> elotuzumab (Empliciti®)</p>	<p> moxetumomab pasudotox * (Lumoxiti®) for hairy cell leukemia</p> <p> tagraxofusp * (Elzonris™) for blastic plasmacytoid dendritic cell neoplasm</p> <p> ibrutinib (Imbruvica®) for graft versus host disease</p> <p> vemurafenib (Zelboraf®) for Erdheim-Chester disease</p>

 Supported by The Leukemia & Lymphoma Society * New therapy ■ Approved in 2018 ■ Approved in 2017 † CAR T-cell immunotherapy

Note: all other therapies were approved as new indications, reformulations of other therapies, new dosing schedules or in combination with another therapy.

LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients

**Research Grant
Programs**

**Therapy
Acceleration
Program[®]**

**Beat AML[®]
Initiative**

Discovery

Development

Service to Patients

TAP progress to date

- >60 projects / >\$115 M invested
- 16 active programs
- 3 FDA-Approved Therapies
 - Vyxeos (AML)
 - Yescarta (DLBCL, tFL, PMBCL)
 - Elzonris (BPDCN)





Beat AML Master Clinical Trial - a demonstration project designed to:


Disrupt the landscape of clinical development

Design clinical trials that are **for patients**


Change the paradigm of treatment: precision medicine

Accelerate drug registration for first-line AML treatment

Beat AML Master Trial approach



Collaboration is key



The Impact

Beat AML *has changed* how cancer drugs are developed!

- ✓ ***Making precision medicine a reality*** for patients
- ✓ New model for clinical trials: ***testing 9 drugs simultaneously***
- ✓ Pushing the boundaries of technology: ***FDA-ready in real time***
- ✓ ***Reducing costs 25-30%***
- ✓ Setting collaboration as ***the new standard***
- ✓ **Accelerating timeline** for drug approvals



**BEATING
CANCER
IS IN
OUR BLOOD.**

**A NEW BREED
OF CANCER
NON-PROFIT**

Driving Research
Accelerating Cures



**LEUKEMIA &
LYMPHOMA
SOCIETY®**

Alignment of FY18 Research Commitments with Disease Severity & Incidence

